Abbott isn’t exactly a one-stop pharmaceutical shop, but it’s something close to it. The Illinois-based company has its foot in everything from generic drugs to medical devices to diagnostic tools—and the latter has been particularly significant during the coronavirus pandemic. After 21 years at the helm as chief executive, Miles White was replaced with Robert Ford as CEO on March 31, 2020. Talk about a rough time to take the reins. As part of its efforts to tackle COVID, the company developed a rapid response diagnostic called ID NOW which can conduct such tests on site rather than have to ship them to a lab. That testing business helped it beat Wall Street expectations in July 2020 with COVID diagnostics alone adding $615 million to the company’s revenues.